Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.
A ‘rising fog’ may cloud the immune system’s ability to detect tumors and may be the key to tackling lung cancer that is developing years before diagnosis. The team at University College London (UCL) followed this signal using prototype blood tests and reversed it using drugs.
Neuroblastoma is the most common solid tumor found outside the brain in children, yet why some children respond well to treatment while others do not has remained poorly understood.
Our bodies contain immune cells called macrophages. Normally, these cells attack and suppress bacteria and cancer cells. However, when macrophages infiltrate tumors, they can become tumor-associated macrophages (TAMs) and can switch to an immunosuppressive, anti-inflammatory state.
SEATTLE and SAN DIEGO, Oct. 8, 2026 /PRNewswire/ — Monod Bio and BPS Bioscience today announced a non-exclusive licensing agreement covering Monod Bio’s LuxSit Pro de novo luciferase and NovoBody binding proteins. BPS plans to integrate the technologies into the development of innovative research products and services for drug discovery and life science applications.